An observational study in Ulcerative Colitis (UC), sponsored by Ataturk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Ataturk University · Observational
The aim of this study is to demonstrate the type and amount of retention in the colon during ulcerative colitis activation, as well as the relationship between C-reactive protein (CRP), albumin and the calculated CALLY index. The investigators also aim to establish whether this ratio can be used to indicate activation.
1,492 studies on the registry are indexed under Colitis, Ulcerative; 399 are open to participants now.
This study's enrollment of 100 is below the median of 157 across 395 observational studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Ataturk University is the lead sponsor of 442 studies on the registry; 121 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Ulserative colitis patients
Exclusion Criteria:
The CALLY index, integrating C-reactive protein (CRP), albumin, and lymphocyte count, has been identified as a promising prognostic biomarker.
The HALP score is calculated as HALP Score = \[hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)\]/platelets (/L). It is a definitive biomarker.
Change in Patients' HALP Score
Ulcerative colitis patients will be evaluated by evaluating the Change in HALP Score and its effect on prognosis.
Time frame: through study completion, an average of 1 year
Change in Patients' CALLY Index Score
Ulcerative colitis patients will be evaluated by evaluating the Change in CALLY Index Score and its effect on prognosis.
Time frame: through study completion, an average of 1 year
Plan to share: Undecided
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ataturk University